FARXIGA Market

“FARXIGA Market Size, Forecast, and Market Insight − 2032” report provides comprehensive insights about FARXIGA for Diabetic Kidney Disease (DKD) in the seven major markets. A detailed picture of the FARXIGA for DKD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the FARXIGA for DKD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FARXIGA market forecast analysis for DKD in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in DKD.

Drug Summary

FARXIGA/FORXIGA (dapagliflozin) is a first-in-class, oral, once-daily SGLT2 inhibitor that reduces the re-absorption of filtered glucose and promotes urinary glucose excretion. Research has shown Forxiga’s efficacy in preventing and delaying cardiorenal disease while also protecting the organs, important findings given the underlying links between the heart, kidneys and pancreas. 

The drug is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus, and either established cardiovascular disease or multiple cardiovascular risk factors; to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (NYHA Class II–IV); to reduce the risk of sustained eGFR decline, end-stage kidney disease cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.

Mechanism of action

Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the re-absorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces the re-absorption of filtered glucose and thereby promotes urinary glucose excretion. Dapagliflozin also reduces sodium re-absorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, lowering both pre- and afterload of the heart and downregulation of sympathetic activity, and decreased intraglomerular pressure which is believed to be mediated by increased tubuloglomerular feedback. 

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the FARXIGA description, mechanism of action, dosage and administration, research and development activities in Diabetic Kidney Disease (DKD).
• Elaborated details on FARXIGA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the FARXIGA research and development activities in DKD across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around FARXIGA.
• The report contains forecasted sales of FARXIGA for DKD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DKD.
• The report also features the SWOT analysis with analyst views for FARXIGA in DKD.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FARXIGA Analytical Perspective by DelveInsight

• In-depth FARXIGA Market Assessment

This report provides a detailed market assessment of FARXIGA for Diabetic Kidney Disease (DKD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• FARXIGA Clinical Assessment

The report provides the clinical trials information of FARXIGA for Diabetic Kidney Disease (DKD) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights  

• In the coming years, the market scenario for Diabetic Kidney Disease (DKD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FARXIGA dominance.
• Other emerging products for DKD are expected to give tough market competition to FARXIGA and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FARXIGA in DKD.
• Our in-depth analysis of the forecasted sales data of FARXIGA from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FARXIGA in DKD. 

Key Questions

• What is the product type, route of administration and mechanism of action of FARXIGA?
• What is the clinical trial status of the study related to FARXIGA in Diabetic Kidney Disease (DKD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FARXIGA development?
• What are the key designations that have been granted to FARXIGA for DKD?
• What is the forecasted market scenario of FARXIGA for DKD?
• What are the forecasted sales of FARXIGA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging products available and how are these giving competition to FARXIGA for DKD?
• Which are the late-stage emerging therapies under development for the treatment of DKD?